Merck Serono and EPFL Announce Research Partnership

November 6, 2007
BioPharm International Editors

Merck Serono (Geneva, Switzerland), a division of Merck KGaA, and Ecole Polytechnique Fédérale de Lausanne (EPFL, Lausanne, Switzerland) have entered into a research collaboration agreement in neuroscience, oncology, and drug delivery.

Merck Serono (Geneva, Switzerland), a division of Merck KGaA, and Ecole Polytechnique Fédérale de Lausanne (EPFL, Lausanne, Switzerland) have entered into a research collaboration agreement in neuroscience, oncology, and drug delivery. Under the agreement, three Merck Serono endowed chairs will be created at EPFL in neurodegenerative diseases, cancer, and innovative drug delivery technologies, for which Merck Serono will make a total donation of $10.8 million. Merck Serono will also open a research fund at EPFL of up to $2.6 million per year over five years.

This agreement between Merck Serono and EPFL underlines the potential of transdisciplinary projects that bring together expertise and resources in life sciences, basic sciences, information technology, and engineering. The partnership’s success will be confirmed through novel therapeutic strategies, academic performance (scientific publications and conferences), and educational opportunities.